<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507608</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00167697</org_study_id>
    <nct_id>NCT03507608</nct_id>
  </id_info>
  <brief_title>Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression</brief_title>
  <official_title>Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, two-phase study to assess the efficacy of single
      pulsed-dose flutamide in creating double strand breaks (DSBs) in prostate cancer within
      patients receiving central androgen suppression and brachytherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-center, two-phase study to assess the efficacy of single
      pulsed-dose flutamide in creating DSBs (double strand breaks) in prostate cancer within
      patients receiving central androgen suppression and brachytherapy. The initial phase is a
      6-patient single-arm run-in phase to test feasibility and rule out futility of the
      intervention. All patients within the run-in phase will receive 50mg flutamide prior to
      brachytherapy and prostatic biopsy. If futility is ruled out (&gt;1 patients with DSBs on
      biopsy), then accrual will continue in the randomized, double-blind phase. Subjects will be
      randomized in a 2:1 ratio (12:6 patients), for an all-trial total of 18 patients receiving
      flutamide vs 6 patients receiving placebo.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The initial phase is a 6-patient single-arm run-in phase to test feasibility and rule out futility of the intervention. All patients within the run-in phase will receive 50mg flutamide prior to brachytherapy and prostatic biopsy. If futility is ruled out (&gt;1 patients with DSBs on biopsy), then accrual will continue in the randomized in a 2:1 ratio (12:6 patients), for an all-trial total of 18 patients receiving flutamide vs 6 patients receiving placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to DNA double strand break</measure>
    <time_frame>6-9 months</time_frame>
    <description>To confirm DNA double strand breaks occur in prostate cancer tissue following pulse-dose flutamide administration in patients who are androgen suppressed, as compared to control patients receiving placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>flutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg flutamide prior to brachytherapy and prostatic biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo prior to brachytherapy and prostatic biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flutamide</intervention_name>
    <description>50mg flutamide prior to brachytherapy and prostatic biopsy</description>
    <arm_group_label>flutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo prior to brachytherapy and prostatic biopsy</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed prostate cancer

          -  At least one biopsy core with Gleason 7 or higher disease

          -  The patient has decided to undergo brachytherapy plus androgen suppression as
             treatment modality for his prostate cancer (with or without supplemental external beam
             radiation)

          -  Suitable volume of disease for biopsy:

          -  clinically palpable disease corresponding to (ipsilateral to) any involved core on
             biopsy

          -  Signed study-specific consent form prior to registration

        Exclusion Criteria:

          -  Known hypersensitivity or allergic response to flutamide

          -  Severe hepatic impairment

          -  Major medical or psychiatric illness which, in the investigator's opinion, would
             prevent completion of treatment and would interfere with follow up.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>males with prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Song, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SKCCC at Johns Hopkins</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Song, M.D.</last_name>
    <phone>410-502-5875</phone>
    <email>dsong2@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shirley DiPasquale, R.N.</last_name>
    <phone>410-614-1598</phone>
    <email>sdipasq1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SKCCC at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Song, M.D.</last_name>
      <phone>410-502-5875</phone>
      <email>dsong2@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shirley DiPasquale, R.N</last_name>
      <phone>410-614-1598</phone>
      <email>sdipasq1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Srinivasan Yegnasubramanian, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore DeWeese, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Coulter, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelo Demarzo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Gorin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen Hu, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Flutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

